NEW YORK (GenomeWeb News) – Rosetta Genomics announced after the close of the market on Thursday it has entered into definitive agreements with investors to raise $6.6 million in a direct offering.

The agreement calls for investors to purchase an aggregate of 570,755 ordinary shares at a price of $11.50 per share. The offering is expected to close on or about May 31, the Israel-based molecular diagnostic company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.